Validation studies across a heterogeneous panel of patient-derived GBM stem cells demonstrated potent FAK+MEK inhibitor combination activity at nanomolar concentrations in 2D and 3D phenotypic assays and reduced tumor area in an in vivo orthotopic transplantation model. The gene discussed is MAP2K7; the disease is glioblastoma.